Edgar Filing: eXegenics Inc

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Eichler David A

2. Issuer Name and Ticker or Trading Symbol
eXegenics Inc [EXEG]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

625 AVENUE OF THE AMERICAS

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2007

(Street)

NEW YORK, NY 10011

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series C Convertible Preferred Stock

$ 0

03/27/2007

J⁽¹⁾

90,815

⁽²⁾

Common Stock

9,081,500

$ 0

90,815

See Footnote ⁽³⁾

Warrant (Right to Buy)

$ 0.002

03/27/2007

J⁽¹⁾

1,135,188

⁽⁴⁾

03/27/2017

Common Stock

1,135,188

$ 0

1,135,188

See Footnote ⁽³⁾

Warrant(Right to Buy)

$ 0.6728

03/27/2007

J⁽¹⁾

309,737

⁽⁴⁾

03/27/2017

Common Stock

309,737

$ 0

309,737

See Footnote ⁽³⁾

Warrant (Right to Buy)

$ 0.8473

03/27/2007

J⁽¹⁾

309,737

⁽⁴⁾

03/27/2017

Common Stock

309,737

$ 0

309,737

See Footnote ⁽³⁾

Warrant (Right to Buy)

$ 1.0466

03/27/2007

J⁽¹⁾

309,737

⁽⁴⁾

03/27/2017

Common Stock

309,737

$ 0

309,737

See Footnote ⁽³⁾

Stock Option (Right to Buy)

$ 0.04

03/27/2007

J⁽¹⁾

25,947

⁽⁵⁾

11/08/2014

Common Stock

25,947

$ 0

25,947

See Footnote ⁽³⁾

Stock Option (Right to Buy)

$ 0.04

03/27/2007

J⁽¹⁾

103,788

⁽⁵⁾

02/15/2015

Common Stock

103,788

$ 0

103,788

See Footnote ⁽³⁾

Stock Option (Right to Buy)

$ 0.05

03/27/2007

J⁽¹⁾

155,682

⁽⁶⁾

02/28/2016

Common Stock

155,682

$ 0

155,682

See Footnote ⁽³⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Eichler David A 625 AVENUE OF THE AMERICAS NEW YORK, NY 10011	X

Signatures

/s/ David A. Eichler		03/29/2007
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc.
(2)	These shares are currently exercisable and do not expire.
(3)	As Managing Director of Psilos Group Investors II-S, LLC, the General Partner of Psilos Group Partners II SBIC, L.P.
(4)	These warrants are currently exercisable.
(5)	These options are fully vested.
(6)	56,218.83 of these options are fully vested. The balance will vest monthly until fully vested in December 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.